Dr. John Cush RheumNow
2 years 4 months ago
PNAS: Autoimmunity against MDA5 induces fibrotic ILD in mice. In this murine model of dermatomyositis, treatment with either anti-CD4 or anti-IL-6 receptor antibody ameliorated the MDA5-induced fibrotic ILD. https://t.co/CahyGfTn4g https://t.co/lfpdgEvGmx
Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficient interventions for those affected with mucosal or systemic manifestations.
Dr. John Cush RheumNow
2 years 4 months ago
ICYMI: Sex Disparities in PsA/SpA
https://t.co/55zwjR8mNR https://t.co/fhhekNpHVA
Dr. John Cush RheumNow
2 years 4 months ago
ILD Onset in MDA-5 Dermatomyositis
MDA5 antibody-positive DM is a rare, aggressive and progressive subtype of DM. Its' severity is dependent on the development of progressive ILD, manifesting as either RPILD and CILD.
https://t.co/08wAYj06DH https://t.co/TQWHGR27O9
Dr. John Cush RheumNow
2 years 4 months ago
World Congress on OP, OA & MSK Disorders
Bone and musculoskeletal disease researchers and physicians from around the world will meet today in London for the opening of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
https://t.co/kzvWD4Rmki https://t.co/PJQREsJO9v
Dr. John Cush RheumNow
2 years 4 months ago
Neuropsychiatric SLE - 2/3 Improved at 12 Months
The management and outcomes of neuropsychiatric systemic lupus erythematosus (NPSLE) can be challenging as there is limited data.
https://t.co/p0GEtkUTdt https://t.co/EZhjH6PxWQ
Dr. John Cush RheumNow
2 years 4 months ago
TNFi mAbs, JAKi, –IL-17 are protective against Anterior Uveitis (AU) in AxSpA. Metanalysis of 44 RCTs shows AU IR:
- TNF mAbs: 4.1
- etanercept 5.4
- IL-17i: 2.8
- JAKi: 1.5
- placebo: 10.8 https://t.co/sxqCXkD0up https://t.co/XWXUPmCtZr
Once again RheumNow Live 2024 really delivered with high impact learning packed into short sessions. As someone with an interest in vasculitis it was fantastic to see four of my favorite speakers in the Vasculitis Mavens and STEP talks. They gave us what we really want from these talks – personal opinions and approaches that go beyond the guidelines. They really dropped a selection of pearls on us and I wanted to share a few of these with you.
A prospective study from the Netherlands analyzed the comparative value of simultaneous labial and parotid salivary gland biopsies performed in patients with sicca complaints and suspected Sjogren's syndrome (SjD).
Dr. John Cush RheumNow
2 years 4 months ago
Of 375 #Gout pts D/C pegloticase after a median of 8 infusions (taken 112days (max 1,240d). Only 73% had SUA < 6 during pegloticase. After D/C 84% went on ULT (63% allopurinol; 34% febuxostat; after mean 92d); after ≥ 30 days), 51% achieved SUA < 6 https://t.co/unkvt1whrs https://t.co/DgVpBgKXcm
Dr. John Cush RheumNow
2 years 4 months ago
Mental health in 1150 adolescents & young adults w/ juvenile idiopathic arthritis (age 15.6 yrs; Dz duration 7.2 yrs, 43% oligo-, 26% polyarthritis): 30% reported suicidal thoughts, 19% mod-severe depressive/anxious Sxs (moreso in Females OR 2.33) https://t.co/THW1IMqZpa https://t.co/IU2Kr3efYj
Dr. John Cush RheumNow
2 years 4 months ago
ICYMI: Top 5 Clinical Pearls in RA Management
https://t.co/zWRXzHTtIo https://t.co/rbitB9oWQG
Dr. John Cush RheumNow
2 years 4 months ago
Canadian OBRI study in 692 RA pts shows pts treated w/ triple DMARD (MSH) stayed on Rx longer (15 mos) compared to MTX+LEF (9.6 mos); not significant but MTX/SSZ/HCQ had signif lower DAS28 @ 6 mos (3.4 vs 3.9) & at 12 mos (3.2 vs 3.5, p=0.0005) https://t.co/ieHeXvgj3n https://t.co/MEMA1nrUpy
Dr. John Cush RheumNow
2 years 4 months ago
Join us 4/16 for Tuesday Night Rheumatology at 6:30pm ET. This week we'll be focusing on Vasculitis Mavens with:
Vasculitis & Pregnancy - Catherine Sims, MD
GPA Management in 2024 - Anisha Dua, MD, MPH
Treat to Target in Vasculitis - Philip Seo, MD
https://t.co/6IaCdCodGf https://t.co/HlZ8OiZWc4

